Myriad Genetics anticipates reporting total molecular diagnostic revenue, which represents the bulk of the company’s revenue, of approximately $86 million for the fourth quarter of fiscal 2009, ending
Cephalon has submitted a supplemental New Drug Application (sNDA) to FDA for Nuvigil (armodafinil) tablets. It is for the indication of improved wakefulness in patients with excessive sleepiness
XenoPort has reported positive preliminary results from a phase-II clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to
Golden Meditech has posted its annual results for the year ended 31 March 2009. The company recorded turnover of HK$498 million, representing an increase of 18% from last
AstraZeneca has announced that its development partner, Pozen has submitted a New Drug Application (NDA) to the FDA, for VIMOVO (PN400) tablets. PN400 is under investigation for the
Novavax has signed initial agreement with Spanish Government to license proprietary, recombinant virus-like-particle (VLP) vaccine technology, to Rovi of Spain. Rovi will use the VLP technology to create
Wyeth and Catalyst have entered into a collaboration for the discovery, development and commercialization of Factor VIIa products, to treat hemophilia and other bleeding conditions. Under the collaboration,
Sanofi-Aventis has presented its new R&D model project. The model, which aims to transform R&D and increase innovation, is the first step of the group’s new strategy which
Peregrine has completed the patient enrollment in its US Phase I clinical trial, evaluating bavituximab as monotherapy in patients with advanced refractory cancers. The objectives of this multi-center
Amira has reported initial positive data from Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. It is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.